Heart failure in the Veneto region of Italy: analysis of therapeutic pathways and the utilization of healthcare resources

References

• World Health Organization. Cardiovascular diseases (CVDs). [cited 2019 Apr 16]. Available from: http://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).html
   Google Scholar
• McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. Eur Heart J. 2012;33:1787–1847.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart failure society of America. Circulation. 2016;2016(134):e282–93.
   Google Scholar
• Chang LL, Xu H, DeVore AD, et al. Timing of post discharge follow-up and medication adherence among patients with heart failure. J Am Heart Assoc. 2018;7:e007998.
   PubMed Web of Science ®Google Scholar
• Fitzgerald AA, Powers JD, Ho PM, et al. Impact of medication nonadherence on hospitalizations and mortality in heart failure. J Card Fail. 2011;17:664–669.
   PubMed Web of Science ®Google Scholar
• Franco G, Biagio F, Battista ZG, et al. ALERT-HF: adherence to guidelines in the treatment of patients with chronic heart failure. J Cardiovasc Med (Hagerstown). 2014;15:491–497.
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Orso F, Calabria S, et al. The real-world evidence of heart failure: findings from 41 413 patients of the ARNO database. Eur J Heart Fail. 2016;18:402–410.
   PubMed Web of Science ®Google Scholar
• Iacoviello M, Pede S, Aspromonte N, et al. The APULIA HF multicenter study: efficacy of a management protocol shared between hospital and territorial health services for acute decompensated heart failure patients. G Ital Cardiol (Rome). 2017;18:150–158.
   PubMedGoogle Scholar
• Avaldi VM, Lenzi J, Urbinati S, et al. Effect of cardiologist care on 6-month outcomes in patients discharged with heart failure: results from an observational study based on administrative data. BMJ Open. 2017;7:e018243.
   PubMed Web of Science ®Google Scholar
• Marangoni E, Lissoni F, Raimondi Cominesi I, et al. Heart failure: epidemiology, costs and healthcare programs in Italy. G Ital Cardiol (Rome). 2012;13:139s–44s.
   PubMedGoogle Scholar
• Maggioni AP, Spandonaro F. Acute heart failure in Italy. G Ital Cardiol (Rome). 2014;15:3s–4s.
   PubMedGoogle Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975.
   PubMed Web of Science ®Google Scholar
• Corrao G, Ghirardi A, Ibrahim B, et al. Burden of new hospitalization for heart failure: a population-based investigation from Italy. Eur J Heart Fail. 2014;16:729–736.
   PubMed Web of Science ®Google Scholar
• Agenzia Italiana del Farmaco (AIFA). Guideline for the classification and conduction of the observational studies on medicines. [cited 2019 Apr 16]. Available from: https://www.agenziafarmaco.gov.it/ricclin/sites/default/files/files_wysiwyg/files/CIRCULARS/Circular%2031st%20May%202010.pdf.
   Google Scholar
• Lam CSP, Gamble GD, Ling LH, et al. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. Eur Heart J. 2018;39(20):1770–1780.
   PubMed Web of Science ®Google Scholar
• Senni M, Gavazzi A, Oliva F, et al. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF outcome registry. Int J Cardiol. 2014;173(2):163–169.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet. 2003;362:759–766.
   PubMed Web of Science ®Google Scholar
• Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456–2467.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381:29–39.
   PubMed Web of Science ®Google Scholar
• Kotecha D, Manzano L, Krum H, et al. Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ. 2016;353:i1855.
   PubMedGoogle Scholar
• World Health Organization. Adherence to long-term therapies - evidence for action. [cited 2019 Apr 16]. Available from: http://apps.who.int/medicinedocs/en/d/Js4883e/5.html.
   Google Scholar
• Stewart S, Jenkins A, Buchan S, et al. The current cost of heart failure to the national health service in the UK. Eur J Heart Fail. 2002;4(3):361–371.
   PubMed Web of Science ®Google Scholar
• Neumann T, Biermann J, Neumann A, et al. Heart failure: the commonest reason for hospitalization in Germany—medical and economic perspectives. Deutsches Aerzteblatt Online. 2009;106(16):269–275.
   PubMed Web of Science ®Google Scholar